Viatris Business Model Canvas

Prepare dossiers, manage global filings and maintain licenses across a marketed portfolio of ~1,400 products in more than 165 countries, supporting timely market access and lifecycle changes.

Operate robust QA/QC programs, GMP audits and serialization to secure supply integrity, backed by a global workforce of ~18,000 and integrated quality systems.

Conduct pharmacovigilance, risk management plans and continuous compliance monitoring to manage safety signals and regulatory risk across multi-country portfolios.

R&D focuses on complex generics, biosimilars and differentiated formulations, supported by analytical comparability, bioequivalence and targeted clinical studies to de-risk launches; Viatris leverages a global portfolio of 1,400+ marketed medicines across 165+ countries. Manufacturing optimization and device-drug integration reduce COGS and time-to-market, while internal programs and external partnerships refresh the pipeline and drive commercial sustainability.

Viatris offers branded, generic and biosimilar assets across major therapeutic areas, supporting a portfolio of over 1,400 approved molecules as of 2024. The range spans essential medicines plus complex injectables and inhalation therapies. Lifecycle-managed SKUs sustain market presence, with registrations in more than 165 countries enabling broad accessibility.

Viatris maintains over 40 GMP-compliant manufacturing facilities across 18 countries, providing scale and flexibility for global supply. Facilities include sterile, biologics and high‑potency capabilities supporting over 1,300 marketed products and complex APIs. Integrated QA and digital manufacturing tools drive batch release and compliance, while capacity supports both tender programs and retail channels across more than 165 countries.

Viatris offers high-quality generics and biosimilars at competitive prices, leveraging a global footprint in more than 165 countries and territories to expand access in developed and emerging markets. Generics typically cost 80–85% less than branded therapies, helping reduce total cost of care for health systems and patients. Viatris supports public health via reliable supply chains and essential-therapy continuity across diverse markets.

Viatris offers a broad portfolio of more than 1,400 marketed medicines across chronic and acute conditions, reaching over 165 countries and territories to enable single-vendor procurement for hospitals and payers. The pipeline includes complex injectables and biosimilars to address unmet needs with differentiated products. Integrated supply and product continuity support care across lines of therapy.

As of 2024 Viatris operates in 165+ countries and—after $11.3B revenue in 2023—deploys dedicated institutional account teams for hospitals, GPOs and public tenders to manage large-volume contracts. Tailored contracts, SLAs and quarterly performance reporting track fill rates and OTD metrics. Joint planning aligns demand forecasts and formulary needs with inventory at regional hubs. Continuous liaison teams resolve supply or quality issues via real-time escalation protocols.

Viatris conducts structured pricing and reimbursement negotiations with payers and governments, leveraging 2024-scale commercial capability after reporting approximately $11.8 billion revenue in fiscal 2024 to support contracting power. Evidence-based HEOR and budget impact models drive discussions, aligning with pharmacoeconomic thresholds and tender terms in markets where public procurement represents a major payer. Compliance programs ensure adherence to tender requirements and lifecycle reporting, with transparent communication on supply availability and product changes to minimize formulary disruption.

Viatris leverages global and regional distributor and wholesaler networks to serve more than 165 countries and markets, expanding reach into hospitals, clinics and pharmacies. The company prioritizes inventory optimization and faster replenishment through regional intermediaries and local warehousing to reduce lead times. Cold-chain integrity and serialization compliance follow DSCSA in the US and FMD in the EU to meet regulatory traceability requirements.

Viatris sells directly to hospitals, health systems and government purchasers, competing in tenders and securing multi-year contracts to supply essential generics and biosimilars. In 2024 Viatris reported approximately $11.5 billion in net product sales, supporting contract negotiations and scale. Deliveries are coordinated to formulary demand with service-level commitments, inventory reporting and KPI dashboards to institutional buyers.

National ministries, tender bodies and public hospitals demand reliable supply chains and competitive pricing, with procurement cycles often favoring suppliers that demonstrate regulatory compliance and manufacturing scale; Viatris, present in more than 165 countries as of 2024, leverages global footprint to meet tenders. Buyers value broad portfolios to consolidate procurement, reduce SKUs and lower transaction costs. Proven compliance reduces bid risk and shortens award timelines.

Inpatient and outpatient hospitals and health systems—about 6,100 hospitals in the US per AHA—prioritize quality, continuity of care, and tight formulary fit when selecting suppliers. They prefer long-term contract stability and robust service/support models to manage supply chains and patient safety. Decision-making relies heavily on clinical evidence and dedicated medical information services to justify formulary inclusion.

Raw materials, active pharmaceutical ingredients and packaging remain the largest components of Viatris COGS, driving price sensitivity across portfolios. Facility operations, energy and labor introduce scale-dependent fixed and variable expenses that rise with production volume. Yield losses and expanded QA/testing cycles compress margins, while 2024 continuous-improvement programs target reduced unit costs through process optimization and yield gains.

Viatris allocates significant R&D and clinical expense — about $680 million in 2024 — to analytical development, bioequivalence studies and clinical trials supporting generics and complex injectables. Device development and comparability workstreams for biosimilars drive specialized CMC spend and longer timelines. Regulatory submissions and global CMC dossiers add regulatory costs, while external partnerships and in-licensing fees further inflate program-level investment.

Volume-driven revenues across retail and hospital channels rely on high unit sales; generics accounted for roughly 90% of US prescriptions by volume in 2024, supporting scale-based margins. Viatris competes on price, availability and breadth, winning tenders and substitution opportunities that lift uptake in hospitals and payor contracts. Ongoing portfolio refresh and new launches in 2024 helped offset price erosion and loss of exclusivities.

Biosimilars deliver higher gross margins than generics, often in the 20–35% range, driven by premium pricing for complex biologic alternatives. Revenues hinge on robust comparability evidence and market access; regulatory approvals and phase IV data in 2024 accelerated launches. Provider education and payer contract wins—rebates and formulary placements—drive uptake, with uptake varying by market (EU >70% for some molecules in 2024, US lower). Global launches remain staggered by IP cliffs and country-by-country exclusivity windows.